AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...
Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for ...
Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...
The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...
Breast cancer drug blocked for NHS use as price talks break down for third time - Nice said it was ‘extremely disappointed’ ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...
Low event rates and short TTRs with warfarin were notable, and questions persist as to which patients truly need OAC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback